PTPN11 and cardiovascular disorder: Precision medicine approaches integrating genomic profiling, cardiovascular risk stratification, and biomarker-guided patient selection will be essential to safely advance SHP2-targeted therapies in oncology, particularly for patients with underlying cardiovascular disease.